Literature DB >> 33154033

Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.

Kate M O'Shea1,2, Orla M O'Carroll3,2, Catherine Carroll3, Brenda Grogan1,3, Anna Connolly3, Lynda O'Shaughnessy3, Trevor T Nicholson3, Charles G Gallagher1,3, Edward F McKone4,3.   

Abstract

Entities:  

Year:  2021        PMID： 33154033     DOI： 10.1183/13993003.03079-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  12 in total

1.  Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence.

Authors:  Yunjie Huang; Grace Paul; Jesun Lee; Sunitha Yarlagadda; Karen McCoy; Anjaparavanda P Naren
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 30.528

2.  The Effect of Elexacaftor/Tezacaftor/Ivacaftor on Hospitalizations and Intravenous Antibiotic Use.

Authors:  Eric Walter; Jennifer L Bass
Journal:  Perm J       Date:  2022-04-05

Review 3.  CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis.

Authors:  Christian Benden; Carsten Schwarz
Journal:  Pulm Ther       Date:  2021-08-18

4.  Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.

Authors:  Vincenzo Carnovale; Paola Iacotucci; Vito Terlizzi; Carmela Colangelo; Lorenza Ferrillo; Angela Pepe; Michela Francalanci; Giovanni Taccetti; Serena Buonaurio; Assunta Celardo; Laura Salvadori; Giovanni Marsicovetere; Michele D'Andria; Nicola Ferrara; Donatello Salvatore
Journal:  J Clin Med       Date:  2022-02-16       Impact factor: 4.241

Review 5.  Challenges in the use of highly effective modulator treatment for cystic fibrosis.

Authors:  Kathleen J Ramos; Joseph M Pilewski; Jennifer L Taylor-Cousar
Journal:  J Cyst Fibros       Date:  2021-01-30       Impact factor: 5.482

6.  Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.

Authors:  Ciaran A Shaughnessy; Pamela L Zeitlin; Preston E Bratcher
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

Review 7.  The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.

Authors:  Caitlyn Harvey; Sinead Weldon; Stuart Elborn; Damian G Downey; Clifford Taggart
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

8.  Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.

Authors:  David P Nichols; Alex C Paynter; Sonya L Heltshe; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Margaret Rosenfeld; Scott D Sagel; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; John P Clancy; Shannon Kirby; Jill M Van Dalfsen; Margaret H Kloster; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2022-03-01       Impact factor: 30.528

Review 9.  New Therapies to Correct the Cystic Fibrosis Basic Defect.

Authors:  Christelle Bergeron; André M Cantin
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

Review 10.  Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series.

Authors:  Christina M Mingora; Patrick A Flume
Journal:  Chest       Date:  2021-06-17       Impact factor: 10.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.